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Abstract
Cancer is a term used to refer to a large set of diseases. The cancerous cells grow
and divide and, as a result, they form tumours that grow in size. The immune sys-
tem recognise the cancerous cells and attack them, though, it can be weakened by
the cancer. One type of cancer treatment is chemotherapy, which uses drugs to kill
cancer cells. Clinical, experimental, and theoretical research has been developed
to understand the dynamics of cancerous cells with chemotherapy treatment, as
well as the interaction between tumour growth and immune system. We study a
mathematical model that describes the cancer growth, immune system response,
and chemotherapeutic agents. The immune system is composed of resting cells
that are converted to hunting cells to combat the cancer. In this work, we consider
drug sensitive and resistant cancer cells. We show that the tumour growth can be
controlled not only by means of different chemotherapy protocols, but also by the
immune system that attacks both sensitive and resistant cancer cells. Furthermore,
for all considered protocols, we demonstrate that the time delay from resting to
hunting cells plays a crucial role in the combat against cancer cells.
Keywords: tumour-immune, chemotherapy, drug resistance
1 Introduction
An abnormal growth of cells can cause a malignant or cancerous tumour to invade
nearby tissues and possibly to spread to other organs [1]. Cancer is a group of diseases,
being a public health problem in all countries of the world [2]. Many types of treatment
have been developed to eliminate cancer cells, such as surgery [3], chemotherapy [4],
and radiation [5]. One of the chemotherapeutic treatments is the immunotherapy [6].
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Mathematical models have been used to study different types of cancer and stages
of tumour progression [7, 8]. In 1972, Greenspan [9] constructed a mathematical
model of tumour growth to analyse the evolution of carcinoma. A model of tumour
induced capillary growth was proposed by Balding and McElwain [10] in 1985. In
the 1990s, Tracqui et al. [11] and Panetta [12] added chemotherapy to study the ef-
fects of chemotherapeutic agents on spatio-temporal growth and tumour recurrence,
respectively. Recently, Lo´pez et al. [13, 14] formulated a model of tumour growth with
cytotoxic chemotherapeutic agents to analyse the role of dose-dense protocols.
The immune system has as its main function to protect the body against infection
and illness. It can recognise the cancerous cells and eliminate them, though, the cancer
can weaken the immunity [15]. The cancer treatment that takes advantage of the im-
mune system is known as immunotherapy [16]. Some therapies based on the immune
system consists of monoclonal antibodies, vaccines, and T-cell transfer [17]. Mathe-
matical and computational studies of cancer immunotherapy have been performed to
understand the interactions between immunity and tumour growth [18, 19]. Borges et
al. [20] presented a tumour-immune model with chemotherapy treatment. They con-
sidered a time-delay between the conversion from resting to hunting cells, the main
immune system reaction. Ren et al. [21] demonstrated analytical result for impulse
chemotherapy parameter to eliminate the cancer cells.
Cancers can develop resistance to chemotherapeutic agents [22]. Drug resistance
is a phenomenon that occurs when cancer cells are unaffected by chemotherapy. Ex-
periments have yielded information about the mechanisms of cancer drug resistance
[23]. Sun et al. [24] modelled drug sensitive and resistant cancer cells in response to
chemotherapeutic treatment. Trobia et al. [25] created a model of brain tumour growth
with drug resistance. They demonstrated that the time interval of the drug application
plays an important role in the treatment to eliminate the cancerous cells.
In this work, we include drug resistance in the tumour-immune model proposed by
Borges et al. [20] and analyse its effect on the system. In our mathematical model, the
immune system is composed of resting and hunting cells, while the cancer is separated
into drug sensitive and drug resistant cells. We consider chemotherapy to combat the
tumour growth. However, the chemotherapeutic agents also attack the immune system.
We show that the tumour growth can be controlled by means of different chemotherapy
protocols.
The paper is organised as follows. In Section 2, we introduce the tumour-immune
system with drug resistance. Section 3 presents our results about the effects of the drug
resistance. In the last Section, we draw our conclusions.
2 Mathematical model
Cancer drug resistance has been a difficulty in chemotherapy cancer treatment [26],
and the challenge is how to identify and avoid the resistance [27]. Many researchers
have carried out tests to find new strategies in the treatment of tumours associated with
drug resistance [28].
In this work, we proposed a mathematical model that describes cancerous cell
growth, where we include cancer drug resistance. The cancer cells are separated into
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sensitive and resistant cells, as they are attacked by the immune system. In the immune
system, the resting cells are converted to hunting cells. We consider that the cancerous
and resting cells have a logistic growth, while the hunting cells have a form of pro-
grammed cell death, known as apoptosis. The chemotherapeutic agent is applied to kill
the cancer, it affects all cells, except the drug resistant cancer cells, as shown in Fig. 1.
Figure 1: (Colour online) Schematic representation of the model.
The model is given by
dCS
dt
= q1CS
(
1−
CS +CR
K1
)
−α1CSH − uF[Z]CS −
p1CSZ
a1+CS
, (1)
dCR
dt
= q2CR
[
1−
CS +CR
K1
]
−α2CRH + uF[Z]CS, (2)
dH
dt
= β1HR(t − τ)− d1H −α3H [CS +CR]−
p2HZ
a2+H
, (3)
dR
dt
= q3R
(
1−
R
K2
)
−β1HR(t − τ)−
p3RZ
a3+R
, (4)
dZ
dt
= Φ−
(
ζ +
g1CS
a1+CS
+
g2H
a2+H
+
g3R
a3+R
)
Z, (5)
where CS and CR are the concentration of drug sensitive and resistant cells (kg.m
−3),
respectively, H is the concentration of hunting cells (kg.m−3), R is the concentration of
resting cells (kg.m−3), Z is the concentration of the chemotherapeutic agent (mg.m−2),
t is the time (day), τ is the delay time from resting to hunting cells, and F(Z) is a
function defined as
F(Z) =
{
0, Z = 0
1, Z > 0
. (6)
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Besides that, pi represents the predation coefficient of the chemotherapeutic agent, ai
corresponds to the rate at which the cells achieve the carrying capacity when there is no
competition and predation, and gi represents the combination rates of the chemothera-
peutic agent with the cells [29]. The parameters pi and gi are related with the strength
of the Holling type 2 interaction functions. Holling [30] proposed types of functional
responses to different types of interactions. The type 2 function describes the response
of many interacting predators and has the characteristics of decelerating the intake rate.
The parameter values that we use in our simulations are given in Table 1.
Table 1: Parameters values according to the literature.
Parameter Values Description
q1 0.18 day
−1 Proliferation
q2 0.18 day
−1 rate [31, 32]
q3 0.0245 day
−1
d1 0.0412 day
−1 Death rate [33]
β1 6.2× 10
−9 (cells · day)−1 Conversion rate [33]
Φ 0− 200 mg(m2.day)−1 Chemotherapy [34, 35]
ζ 0.2 day−1 Absorption rate [20]
u 10−3 day−1 Mutation rate [25]
α1,α2 1.101× 10
−7 (cells · day)−1 Competition
α3 3.422× 10
−10 (cells · day)−1 coefficients [33]
K1 5× 10
6 cells Carrying
K2 1× 10
7 cells capacity [31, 32]
τ 45.6 days Time delay [32]
We introduce the following dimensionless variables cs =CS/KT , cr =CR/KT , h =
H/KT , r = R/KT , and z = ζZ, where KT = K1+K2 and t
∗ = t/day. We consider K∗1 =
K1/KT , K
∗
2 = K2/KT , u
∗ = u day, d∗1 = d1 day, β
∗
1 = β1KT day, Φ
∗ = Φ day, ζ ∗ = ζ
day, q∗i = qi day, α
∗
i = αiKT day, p
∗
i = pi/(ζKT ) day, g
∗
i = gi day, and a
∗
i = ai/KT
(i = 1,2,3). Redefining the variables and removing the stars, we obtain
dcs
dt
= q1cs
(
1−
cs + cr
K1
)
−α1csh− uF[z]cs −
p1csz
a1+ cs
, (7)
dcr
dt
= q2cr
[
1−
cs + cr
K1
]
−α2crh+ uF[z]cs, (8)
dh
dt
= β1hr (t − τ)− d1h−α3h [cs + cr]−
p2hz
a2+ h
, (9)
dr
dt
= q3r
(
1−
r
K2
)
−β1hr(t − τ)−
p3rz
a3+ r
, (10)
dz
dt
= Φζ −
(
ζ +
g1cs
a1+ cs
+
g2h
a2+ h
+
g3r
a3+ r
)
z, (11)
The dimensionless parameter values are given in Table 2.
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Table 2: Dimensionless parameters.
Parameter Values
q1 0.18
q2 0.18
q3 0.0245
d1 0.0412
β1 9.3× 10
−2
p1 1× 10
−3
p2 1× 10
−3
p3 1× 10
−3
a1 1× 10
−4
a2 1× 10
−4
a3 1× 10
−4
g1, g2, g3 0.1
α1,α2 1.6515
α3 5.133× 10
−3
K1 1/3
K2 2/3
3 Tumour drug resistance
Many different powerful chemicals and clinical protocols have been used to elimi-
nate a wide variety of cancers. In this work, we consider both continuous and pulsed
chemotherapy treatments. In our simulations, the initial conditions are given by cs(0)=
0.18, cr(0) = 0.0, h(0) = 0.01, r(0) = 0.48, and z(0) = 0.0.
3.1 Continuous chemotherapy treatment
Figure 2 displays the behaviour of the time evolution of cs (red line), cr (blue line),
h (black line), and r (green line) when there is no cancer drug resistance (u = 0) for
a continuous chemotherapy treatment. Increasing the value of chemotherapy dose Φ
from 0.02 (Fig. 2(a)) to 0.025 (Fig. 2(b)), we observe that the cancer (red line) is killed
while the cells of the immune system (black and green lines) remain alive.
Drug resistance is one of the many problems in the cancer therapy. This phe-
nomenon is considered in our model when the mutation rate u > 0. In Fig. 3, we see
the appearance of drug resistant cancer cells (blue line) due to u = 0.001. Increasing
Φ from 0.02 (Fig. 3(a)) to 0.035 (Fig. 3(b)), we verify a temporary cancer remission
(cs(t)< 0.0009 and cr(t)< 0.0009) for t equal to 434 and 557 days, respectively. The
sensitive cancer cells are suppressed by the chemotherapy and the immune system.
However, the immune system by itself is not sufficient to suppress the resistant cancer
cells.
We compute the parameter space p1×Φ to identify the regions in which the cancer
remission occurs. Figure 4(a) displays the situation without drug resistance, namely
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Figure 2: (Colour online) Time evolution of cs (red line), cr (blue line), h (black line),
and r (green line) for (a) Φ = 0.02 and (b) Φ = 0.025.
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Figure 3: (Colour online) Time evolution of cs (red line), cr (blue line), h (black line),
and r (green line) for u = 0.001, (a) Φ = 0.02, and (b) Φ = 0.035.
for u = 0. We separate into three regions: cancer growth (cs > 0), cancer remission
(cs < 0.001), and hunting cells remission (h < 0.001). The cancer grows for small
values of p1 and Φ (black region), but it is suppressed for larger values (yellow region).
Higher values of these parameters not only lead to the killing cancerous cells, but also
weaken the immune system with the remission of the hunting cells (red region). When
there is drug resistance, the temporary cancer remission for 100 days (0.0≤ cr < 0.01)
is observed for small values of p1 and Φ for u = 0.001, as shown in Fig. 4(b) (yellow
region).
3.2 Pulsed chemotherapy treatment
Pulsed administration of chemotherapeutic drugs, also known as intermittent therapy,
is a clinical protocol in which the drug is administered and followed by a rest period.
In our simulations, we use periodically pulsed chemotherapy and analyse different rest
periods to find cancer remission.
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Figure 4: (Colour online) Parameter space p1×Φ for (a) u = 0.0 and (b) u = 0.001.
We separate into three regions: cancer growth (cs > 0.001, black), cancer remission
(cs < 0.001 and 0.0≤ cr < 0.01, yellow), and hunting cells remission (h < 0.001, red).
Figures 5(a), 5(b), 5(c), and 5(d), exhibit the time evolution of (a) cs, (b) cr, (c)
h, and (d) r, respectively, for Φ = 0.2, u = 0.001, and different protocols (days of
administration× time interval). We do not observe a significant difference between the
protocols 2× 15 (blue line) and 1× 10 (black line). However, both are better than the
protocol 5× 23 (red line), due to the fact that the times for suppression and remission
of cs and cr, respectively, are shorter than 5× 23. The suppression of cs occurs for
t approximately equal to 625 for 5× 23, and about 500 for 2× 15 and 1× 10. The
temporary remission (cr < 0.1) starts approximately 615 days after the chemotherapy
treatment according to the protocol 5×23, and about 450 days for the protocols 2×15
and 1× 10.
The immune system plays an important role in the combat against the cancer.
Thereby, to analyse the influence of the hunting cells on the resistant cancer, we vary
the competition coefficient between the hunting and drug resistant cancer cells (α2),
and the delay time from resting to hunting cells (τ). Figure 6 exhibits the parameter
space α2× τ for the protocol 5× 23, where we consider cancer remission when cs <
0.0001 and cr < 0.1 (yellow region) for at least 100 days, and cancer for cs ≥ 0.0001
and cr ≥ 0.1 (black region). We verify that increasing Φ from 0.2 (Fig. 6(a)) to 0.25
(Fig. 6(b)) the cancer remission region decreases. Therefore, for larger Φ value, the
cancer remission is obtained for smaller τ value.
We also compute the parameter space Φ× τ for the protocols 1×10 and 5×23, as
shown in Figs. 7(a) and 7(b), respectively. Comparing Fig. 7(a) and Fig. 7(b), we see
that not only Φ and τ are important, but also the type of protocol is relevant to increase
the cancer remission region. The cancer remission region is smaller for 5× 23 than
1× 10.
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Figure 5: (Colour online) Time evolution of (a) cs, (b) cr, (c) h, and (d) r for Φ = 0.2
and u = 0.001. We consider the protocols (days of administration× time interval):
5× 23 (red line), 2× 15 (blue line), and 1× 10 (black line).
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Figure 6: (Colour online) Parameter space α2× τ for the protocol 5× 23, (a) Φ = 0.2,
and (b) Φ = 0.25. The yellow and black regions correspond to the cancer remission
and cancer.
4 Conclusions
Drug resistance is responsible for a vast majority of cancer deaths and it is one of the
major challenges in chemotherapy treatment. Initially some cancers are susceptible to
chemotherapeutic agents, however over time they can become resistant. Due to this
fact, strategies have been used to eliminate resistant cancer cells.
In this work, we study the effects of the drug resistance in the tumour-immune sys-
tem with chemotherapy treatment. The immune system is composed of resting cells
that can transform into hunting cells. We separate the cancer into drug sensitive and
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Figure 7: (Colour online) Parameter space Φ× τ for the protocols (a) 1× 10 and (b)
5× 23. The yellow and black regions correspond to the cancer remission and cancer.
drug resistant cells. In our simulations, we consider continuous and pulsed chemother-
apy treatment.
In the continuous chemotherapy treatment, we verify that cancer remission is pos-
sible for smaller values of the chemotherapy intensity and the coefficient of chemother-
apeutic agent on the sensitive cancer cells. The sensitive cells are eliminated, while the
resistant cells are responsible for the remission. With regard to the pulsed chemother-
apy, we analyse three types of protocols (days of administration × time interval):
5× 23, 2× 15, and 1× 10. The protocols 2× 15 and 1× 10 exhibit almost the same
results. In both protocols, the time for the elimination of sensitive cancer cells and the
beginning of the temporary remission are less than the protocol 5× 23. Furthermore,
for all protocols, we show that the time delay from resting to hunting cells plays a
crucial role in the combat against cancer cells.
Our results are in agreement with recent experimental findings related to chemo-
immunotherapy. In 2020, Roemeling et al. [36] carried out treatments to induce im-
mune response against a type of brain tumour. They reported a therapeutic modulation
that is able to generate potent hunting cells. In our model, the hunting cell efficiency
is increased by means of the competition coefficient between hunting cells and cancer
in which the hunting cells kill the cancerous cells. Maletzki et al. [37] in 2019 demon-
strated that the combination of immune-stimulating vaccination and cytotoxic therapy
can improve long-term survival. Depending on the protocol, they observed tumour free
in mice from 25 to 65 weeks. In our simulations, the tumour free occurs about 25
weeks. Nevertheless, for small time delay from resting to hunting cells in our model, it
is possible to use different protocols aiming to maximise the tumour free time.
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